関連文献

Urinary L-FABP: A Novel Biomarker for Evaluating Diabetic Nephropathy Onset and Progression. A Narrative Review.

Diabetes Ther. 2025. doi: 10.1007/s13300-025-01731-w.PubMed

Development of a multiple urinary biomarker model to predict the tubulointerstitial fibrosis area in patients with primary IgA Nephropathy.

BMC Nephrol. 2025. doi: 10.1186/s12882-025-04049-8.PubMed

Estimated Proximal Tubule Fluid Phosphate Concentration and Renal Tubular Damage Biomarkers in Early Stages of Chronic Kidney Disease.

J Ren Nutr. 2024.doi: 10.1053/j.jrn.2024.06.009.PubMed

Topiroxostat-A Safer Uricostatic Drug with Enhanced Renal Protection: A Narrative Review.

J Assoc Physicians India. 2024doi: 10.59556/japi.72.0724.PubMed

Diagnostic Accuracy of L-FABP-to-Creatinine Ratio (LCR) for Prediction of Kidney Damage in Type-2 DM Patients Taking Albumin-to-Creatinine Ratio (ACR) as Gold Standard.

J Pak Soc Intern Med. 2024.doi: jpsim.v5i4.2465JPSIM

Development of Liver Fibrosis Represented by the Fibrosis-4 Index Is a Specific Risk Factor for Tubular Injury in Individuals with Type 2 Diabetes.

Biomedicines. 2024doi: 10.3390/biomedicines12081789.PubMed

Estimated proximal tubule fluid phosphate concentration and renal tubular damage biomarkers in early stages of chronic kidney disease.

J Ren Nutr. 2024doi: 10.1053/j.jrn.2024.06.009.PubMed

Evaluation of Urinary L-FABP as a Tubular Damage Marker in Pediatric Neurogenic Bladder-A Pilot Study.

J Clin Med. 2024doi: 10.3390/jcm13030736.PubMed

Comparison of Urinary Liver Fatty Acid Binding Protein Level and Pathologic Biopsy Findings 1 Year After Kidney Transplantation.

Transplant Proc. 2024doi: 10.1016/j.transproceed.2023.12.016.PubMed

Urinary Liver-Type Fatty Acid Binding Protein, a Biomarker for Disease Progression, Dialysis and Overall Mortality in Chronic Kidney Disease.

J Pers Med. 2023doi: 10.3390/jpm13101481.PubMed

Cross-Sectional and Longitudinal Associations between Skin Autofluorescence and Tubular Injury Defined by Urinary Excretion of Liver-Type Fatty Acid-Binding Protein in People with Type 2 Diabetes.

Biomedicines. 2023doi: 10.3390/biomedicines11113020.PubMed

Elevated urinary angiotensinogen excretion links central and renal hemodynamic alterations.

Sci Rep. 2023doi: 10.1038/s41598-023-38507-wPubMed

Association of urinary liver-type fatty acid-binding protein with outcomes after adrenalectomy for unilateral primary aldosteronism.

Clin Chim Acta. 2023doi: 10.1016/j.cca.2023.117465.PubMed

Increased urinary albumin leakage is related to injuries of glomerular glycocalyx and podocytes, and associated with tubular dysfunction in preeclampsia.

Pregnancy Hypertens. 2023PubMed

Markers of Kidney Tubular Function Deteriorate While Those of Kidney Tubule Health Improve in Primary Aldosteronism After Targeted Treatments.

J Am Heart Assoc. 2023PubMed

Association of urinary liver-type fatty acid-binding protein with renal functions and antihyperglycemic drug use in type 2 diabetic nephropathy patients.

Int Urol Nephrol. 2023PubMed

Clinical utility of tubular markers in kidney disease: a narrative review.

J Lab Precis Med. 2022JLPM

Performance of urinary liver-type fatty acid-binding protein in diabetic nephropathy: A meta-analysis.

Front Med (Lausanne). 2022PubMed

Effects of dietary phosphorus concentration and phosphate salt form on renal tubule function in unilateral nephrectomized rats .

Nutr Health. 2022PubMed

Early, Noninvasive Clinical Indicators of Kidney Prognosis in Primary Nephrotic Syndrome: A Retrospective Exploratory Study .

Int J Nephrol. 2022PubMed

Biomarkers for the early prediction of contrast-induced nephropathy after percutaneous coronary intervention in adults: A systematic review and meta-analysis.

Angiology. 2022PubMed

Usefulness of urinary tubule injury markers for predicting progression of renal dysfunction in patients with type 2 diabetes and albuminuria: The Fukuoka Diabetes Registry.

Diabetes Res Clin Pract. 2022PubMed

Tubular Injury Causing Protracted Glycosuria Following Withdrawal of a Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor: A Possible Role in the Development of Protracted Hypoglycemia and Ketoacidosis.

Tohoku J Exp Med. 2021PubMed

Effect of Dipeptidyl Peptidase-4 (DPP-4) Inhibition on Biomarkers of Kidney Injury and Vascular Calcification in Diabetic Kidney Disease: A Randomized Controlled Trial.

J Diabetes Res. 2021doi: 10.1155/2021/7382620. PubMed

Exercise Ameliorates Diabetic Kidney Disease in Type 2 Diabetic Fatty Rats.

Antioxidants (Basel). 2021PubMed

Clinical evaluation of urinary liver-type fatty acid-binding protein for the diagnosis of renal diseases in dogs.

J Vet Med Sci. 2021PubMed

Amniotic Fluid L-Type Fatty Acid-Binding Protein in Predicting Fetal Condition.

Tohoku J Exp Med. 2021PubMed

Renal hemodynamics across the adult lifespan: Relevance of flow pulsatility to chronic kidney disease.

Exp Gerontol. 2021doi: 10.1016/j.exger.2021.111459. PubMed

Relationship of urinary liver-type fatty acid-binding protein with cardiovascular risk factors in the Japanese population without chronic kidney disease: Sasayama study.

BMC Nephrol. 2021doi: 10.1186/s12882-021-02398-8. PubMed

Preliminary study of urinary excretion of liver-type fatty acid-binding protein in a cat model of chronic kidney disease.

Can J Vet Res. 2021PubMed

Evaluation of urinary L-FABP as an early marker for diabetic nephropathy in type 2 diabetic patients.

J Med Biochem. 2020doi: 10.2478/jomb-2019-0037. PubMed

Liver-type fatty acid-binding protein and neutrophil gelatinase-associated lipocalin in cats with chronic kidney disease and hyperthyroidism.

J Vet Intern Med. 2021doi: 10.1111/jvim.16074. PubMed

Predictive value of novel biomarkers for chronic kidney disease among workers occupationally exposed to silica.

Toxicol Ind Health. 2021doi: 10.1177/0748233721990304. PubMed

Urinary liver-type fatty acid-binding protein is a predictor of mortality in individuals with type 2 diabetes.

Diabet Med. 2021doi: 10.1111/dme.14527.PubMed

Renoprotective effect of GLP-1 receptor agonist, liraglutide, in early-phase diabetic kidney disease in spontaneously diabetic Torii fatty rats.

Clin Exp Nephrol. 2021doi: 10.1007/s10157-020-02007-2.PubMed

Urinary Liver-type Fatty Acid-Binding Protein Predicts Residual Renal Function Decline in Peritoneal Dialysis Patients.

Med Sci Monit. 2020PubMed

Novel Urinary Biomarkers and Chronic Kidney Disease After Coronary Angiography: A Prospective Case-Controlled Study.

Open Access Maced J Med Sci. 2020OAMJMS

Longitudinal kidney injury biomarker trajectories in children with obstructive uropathy.

Pediatr Nephrol. 2020PubMed

Increased Urinary Liver-Type Fatty Acid-Binding Protein Level Predicts Major Adverse Cardiovascular Events in Patients with Hypertension.

Am J Hypertens. 2020PubMed

Renal expression and urinary excretion of liver-type fatty acid-binding protein in cats with renal disease.

J Vet Intern Med. 2020PubMed

Relationship between Urinary Liver-Type Fatty Acid-Binding Protein (L-FABP) and Sarcopenia in Spontaneously Diabetic Torii Fatty Rats.

J Diabetes Res. 2020Hindawi

Effects of exercise on residual renal function in patients undergoing peritoneal dialysis: a post-hoc analysis of a randomized controlled trial.

Ther Apher Dial. 2020PubMed

Evaluation of liver-type fatty acid binding protein (L-FABP) and interleukin 6 in children with renal cysts.

Adv Clin Exp Med. 2019PubMed

The influence of renal function by ibuprofen treatment for patent ductus arteriosus in extremely low-birth-weight infants.

Pediatr Int. 2019PubMed

The Possibility of Urinary Liver-Type Fatty Acid-Binding Protein as a Biomarker of Renal Hypoxia in Spontaneously Diabetic Torii Fatty Rats.

Kidney Blood Press Res. 2019PubMed

Utility of urinary liver-type fatty acid-binding protein as a predictor of renal dysfunction in Japanese patients with HIV receiving tenofovir disoproxil fumarate with low urinary β2 microglobulin levels: a retrospective observational study.

J Pharm Health Care Sci. 2019PubMed

Renoprotective effects of voluntary running exercise training on aldosterone-induced renal injury in human L-FABP chromosomal transgenic mice.

Hypertens Res. 2019PubMed

Effect of linagliptin on oxidative stress markers in patients with type 2 diabetes: a pilot study.

Diabetol Int. 2018PubMed

Urinary Level of Liver-Type Fatty Acid Binding Protein Reflects the Degree of Tubulointerstitial Damage in Polycystic Kidney Disease.

Kidney Blood Press Res. 2018PubMed

Urinary liver-type fatty acid-binding protein levels as a potential risk factor for renal dysfunction in male HIV-infected Japanese patients receiving antiretroviral therapy: a pilot study.

Int J STD AIDS. 2018PubMed

Urinary L-FABP level in children with nephrotic syndrome and tubular dysfunction.

Pediatr Int. 2018PubMed

Anagliptin ameliorates albuminuria and urinary liver-type fatty acid-binding protein excretion in patients with type 2 diabetes with nephropathy in a glucoselowering-independent manner.

BMJ Open Diabetes Res Care. 2017PubMed

Prediction of contrast induced acute kidney injury using novel biomarkers following contrast coronary angiography.

QJM. 2018PubMed

Role of bardoxolone methyl, a nuclear factor erythroid 2-related factor 2 activator, in aldosterone- and salt-induced renal injury.

Hypertens Res. 2017PubMed

Renoprotective effect of the xanthine oxidoreductase inhibitor Topiroxostat under decreased angiotensin II type 1a receptor expression.

Eur J Pharmacol. 2017PubMed

Urinary liver-type fatty acid-binding protein is associated with subendocardial viability ratio in middle- and older-aged adults.

Clin Exp Hypertens. 2017PubMed

Urine liver fatty acid binding protein and chronic kidney disease progression.

Scand J Clin Lab Invest. 2017PubMed

Urinary liver-type fatty acid binding protein is an independent predictor of stroke and mortality in individuals with type 1 diabetes.

Diabetologia. 2017 PubMed

Current Metabolic Status Affects Urinary Liver-Type Fatty-Acid Binding Protein in Normoalbuminuric Patients With Type 2 Diabetes.

JClin Med Res. 2017PubMed

Utility of urinary tubular markers for monitoring chronic tubulointerstitial injury after ischemia-reperfusion.

Nephrology. 2017PubMed

The association between urinary liver-type fatty acid-binding protein and chronic kidney disease classification in HIV-infected Japanese patients.

Clin Exp Nephrol. 2016PubMed

Role of angiotensin II type 1a receptor in renal injury induced by deoxycorticosterone acetate-salt hypertension.

FASEB J. 2016PubMed

Impact of teneligliptin on oxidative stress and endothelial function in type 2 diabetes patients with chronic kidney disease: a case-control study.

Cardiovasc Diabetol. 15(1): 76, 2016.PubMed

Renoprotective effect of the xanthine oxidoreductase inhibitor, Topiroxostat,on Adenine-Induced Renal Injury.

Am J Physiol Renal Physiol. 310(11):F1366-1376, 2016.PubMed

Clinical utility of urinary liver-type fatty acid binding protein measured by latex-enhanced turbidimetric immunoassay in chronic kidney disease.

Clin Chem Lab Med. 2016.PubMed

Clinical significance of urinary liver-type fatty acid-binding protein as a predictor of ESRD and CVD in patients with CKD.

Clin Exp Nephrol. 20(2): 195-203, 2016.PubMed

Urinary markers in the early stage of nephropathy in patients with childhood-onset type 1 diabetes.

Pediatr Nephrol. 31(4):623-631, 2016.PubMed

Epoetin beta pegol alleviates oxidative stress and exacerbation of renal damage from iron deposition, thereby delaying CKD progression in progressive glomerulonephritis rats.

Physiol Rep. 3(12), 2015.PubMed

Urinary liver-type fatty acid-binding protein change in gestational diabetes mellitus.

Diabetes Res Clin Pract. 109(3): e36-e38, 2015.PubMed

Urinary Biomarkers and Risk of ESRD in the Atherosclerosis Risk in Communities Study.

Clin J Am Soc Nephrol. 10(11):1956-1963, 2015.PubMed

Urinary ACE2 is associated with urinary L-FABP and albuminuria in patients with chronic kidney disease.

Scand J Clin Lab Invest. 75(5): 421-427, 2015.PubMed

Does elevation of serum creatinine in patients with chronic hepatitis C under therapy of telaprevir mean renal impairment?

Nephrology. 10(4):e0122212, 2015.PubMed

Distinct roles of urinary liver-type Fatty Acid-binding protein in non-diabetic patients with anemia.

PLoS One. 10(5): e0126990, 2015.PubMed

Circulating TNF Receptors 1 and 2 Are Associated with the Severity of Renal Interstitial Fibrosis in IgA Nephropathy.

PLoS One. 10(4): e0122212, 2015.PubMed

Renoprotective effects of febuxostat in hyperuricemic patients with chronic kidney disease: a parallel-group, randomized, controlled trial.

Clin Exp Nephrol. 19(6): 1044-1053, 2015.PubMed

Association of urinary KIM-1, L-FABP, NAG and NGAL with incident end-stage renal disease and mortality in American Indians with type 2 diabetes mellitus.

Diabetologia. 58(1): 188-198, 2015.PubMed

LDL-apheresis contributes to survival extension and renal function maintenance of severe diabetic nephropathy patients: a retrospective analysis.

Diabetes Res Clin Pract. 106(2): 241-246, 2014.PubMed

NGAL, L-FABP, and KIM-1 in comparison to established markers of renal dysfunction.

Clin Chem Lab Med. 52(4): 537-546, 2014.PubMed

Urinary biomarkers of kidney injury are associated with all-cause mortality in the Women’s Interagency HIV Study (WIHS).

HIV Med. 15(5): 291-300, 2014.PubMed

Level of urinary liver-type fatty acid-binding protein is associated with cardiac markers and electrocardiographic abnormalities in type-2 diabetes with chronic kidney disease stage G1 and G2.

Heart Vessels. 30(3): 362-368, 2014.PubMed

Nonalbuminuric proteinuria as a biomarker for tubular damage in early development of nephropathy with type 2 diabetic patients.

Diabetes Metab Res Rev. 30(8): 736-741, 2014.PubMed

Urine liver-type fatty acid-binding protein and kidney injury molecule-1 in HIV-infected patients receiving combined antiretroviral treatment based on tenofovir.

AIDS Res Hum Retroviruses. 30(4): 363-369, 2014.PubMed

Moderate-intensity single exercise session does not induce renal damage.

J Clin Lab Anal. 27(3): 177-180, 2013.PubMed

A 5-hydroxytryptamine receptor antagonist, sarpogrelate, reduces renal tubulointerstitial fibrosis by suppressing PAI-1.

Am J Physiol Renal Physiol. 305(12): F1796-1803, 2013.PubMed

Predictive effects of urinary liver-type fatty acid-binding protein for deteriorating renal function and incidence of cardiovascular disease in type 2 diabetic patients without advanced nephropathy.

Diabetes Care. 36(5): 1248-1253, 2013.PubMed

Spironolactone diminishes urinary albumin excretion in patients with type 1 diabetes and microalbuminuria: a randomized placebo-controlled crossover study.

Diabet Med. 29(8): e184-190, 2012.PubMed

Renoprotective and antioxidant effects of cilnidipine in hypertensive patients.

Hypertens Res. 35(11): 1058-1062, 2012.PubMed

Potential Benefit of Statin Therapy for Dyslipidemia with Chronic Kidney Disease: Fluvastatin Renal Evaluation Trial (FRET).

Internal Medicine. 50(12): 1273-1278, 2011.PubMed

Additive antioxidative effects of azelnidipine on angiotensin receptor blocker olmesartan treatment for type 2 diabetic patients with albuminuria.

Hypertens Res . 34: 935-941, 2011.PubMed

Protective effects of tubular liver-type fatty acid-binding protein against glomerular damage in murine IgA nephropathy.

Nephrol Dial Transplant. 26(7): 2127-2137, 2011.PubMed

Protective effects of L-type fatty acid-binding protein (L-FABP) in proximal tubular cells against glomerular injury in anti-GBM antibody-mediated glomerulonephritis.

Nephrol Dial Transplant. 26(11): 3465-3473, 2011.PubMed

Clinical significance of urinary liver-type fatty acid-binding protein in diabetic nephropathy of type 2 diabetic patients.

Diabetes Care. 34(3): 691-696, 2011.PubMed

Urinary L-FABP and anaemia: distinct roles of urinary markers in type 2 diabetes.

Eur J Clin Invest. 40(2): 95-102, 2010.PubMed

Urinary liver-type fatty acid-binding protein predicts progression to nephropathy in type 1 diabetic patients.

Diabetes Care. 33(6): 1320-1324, 2010.PubMed

Comparative effects of benidipine and amlodipine on proteinuria, urinary 8-OHdG, urinary L-FABP, and inflammatory and atherosclerosis markers in early-stage chronic kidney disease.

Am J Med Sci. 339(2): 157-163, 2010.PubMed

Renoprotective Effects of Various Angiotensin II Receptor Blockers in Patients with Early-Stage Diabetic Nephropathy.

Kidney Blood Press Res. 33(3): 213-220, 2010.PubMed

Effects of telmisartan and enalapril on renoprotection in patients with mild to moderate chronic kidney disease.

Eur J Clin Invest. 40(9): 790-796, 2010.PubMed

Urinary fatty acids and liver-type fatty acid binding protein in diabetic nephropathy.

Nephron Clin Pract. 112(3): c148-156, 2009.PubMed

Tubular and glomerular injury in diabetes and the impact of ACE inhibition.

Diabetes Care. 32(9): 1684-1688, 2009.PubMed

Effect of red wine on urinary protein, 8-hydroxydeoxyguanosine, and liver-type fatty acid-binding protein excretion in patients with diabetic nephropathy.

Metabolism. 58(8): 1185-1190, 2009.PubMed

Amelioration of diabetic tubulointerstitial damage in liver-type fatty acid-binding protein transgenic mice.

Nephrol Dial Transplant. 24(3): 788-800, 2009.PubMed

Renoprotective effect of telmisartan in patients with chronic kidney disease.

Clin Exp Hypertens. 30(7): 662-672, 2008.PubMed

Additional renoprotective effects of azelnidipine combined with angiotensin receptor blockers in patients with diabetic nephropathy.

Clin Nephrol. 70(5): 385-392, 2008.PubMed

Angiotensin II receptor antagonist reduces urinary liver-type fatty acid-binding protein levels in patients with diabetic nephropathy and chronic renal failure.

Diabetologia. 50(2): 490-492, 2007.PubMed

Azelnidipine reduces urinary protein excretion and urinary liver-type fatty acid binding protein in patients with hypertensive chronic kidney disease.

Am J Med Sci. 333(6): 321-326, 2007.PubMed

Beneficial effects of olmesartan and temocapril on urinary liver-type fatty acid-binding protein levels in normotensive patients with immunoglobin A nephropathy.

Am J Hypertens. 20(11): 1195-1201, 2007.PubMed

Cigarette smoking affects urinary liver-type fatty acid-binding protein concentration in patients with early diabetic nephropathy.

Diabetes Care. 29(7): 1717, 2006.PubMed

Urinary liver-type fatty acid-binding protein levels for differential diagnosis of idiopathic focal glomerulosclerosis and minor glomerular abnormalities and effect of low-density lipoprotein apheresis.

Clin Nephrol. 65(1): 1-6, 2006.PubMed

Effect of pioglitazone on urinary liver-type fatty acid-binding protein concentrations in diabetes patients with microalbuminuria.

Diabetes Metab Res Rev. 22(5): 385-389, 2006.PubMed

Effect of Erythropoietin on Urinary Liver-Type Fatty-Acid-Binding Protein in Patients with Chronic Renal Failure and Anemia.

Am J Nephrol. 26(3): 276-280, 2006.PubMed

Effect of pitavastatin on urinary liver-type fatty-acid-binding protein in patients with nondiabetic mild chronic kidney disease.

Am J Nephrol. 26(1): 82-86, 2006.PubMed

Liver-type fatty acid-binding protein attenuates renal injury induced by unilateral ureteral obstruction.

Am J Pathol. 169(4): 1107-1117, 2006.PubMed

Urinary liver-type fatty acid binding protein as a useful biomarker in chronic kidney disease.

Mol Cell Biochem. 284(1-2): 175-182, 2006.PubMed

Clinical Significance of Urinary Liver-Type Fatty acid-binding Protein in Patients With Diabetic Nephropathy.

Diabetes Care. 28(18): 2038-2039, 2005.PubMed

Candesartan reduces urinary fatty acid-binding protein excretion in patients with autosomal dominant polycystic kidney disease.

TAm J Med Sci. 330(4): 161-165, 2005.PubMed

Effect of Pitavastatin on Urinary Liver-Type Fatty acid-binding Protein Levels in Patients With Early Diabetic Nephropathy.

Diabetes Care. 28(11): 2728-2732, 2005.PubMed

Urinary liver-type fatty acid-binding protein: discrimination between IgA nephropathy and thin basement membrane nephropathy.

Am J Nephrol. 25(5): 447-450, 2005.PubMed

Clinical evaluation of urinary excretion of liver-type fatty acid-binding protein as a marker for the monitoring of chronic kidney disease: A multicenter trial.

J Lab Clin Med. 145(3): 125-133, 2005.PubMed

Urinary excretion of liver fatty acid-binding protein in health-check participants.

Clin Exp Nephrol. 9(1): 34-39, 2005.PubMed

Urinary excretion of fatty acid-binding protein reflects stress overload on the proximal tubules.

Am J Pathol. 165(4): 1243-1255, 2004.PubMed

Urinary fatty acid-binding protein as a new clinical marker of the progression of chronic renal disease.

J Lab Clin Med. 143(1): 23-30, 2004.PubMed

Combination of urinary biomarkers can predict cardiac surgery-associated acute kidney injury: a systematic review and meta-analysis.

Ann Intensive Care. 2025. doi: 10.1186/s13613-025-01459-7.PubMed

Urinary biomarkers in prediction of subclinical acute kidney injury in pediatric oncology patients treated with nephrotoxic agents.

BMC Nephrol. 2025. doi: 10.1186/s12882-025-04085-4.PubMed

Liver fatty acid-binding protein point-of-care testing detects heat-induced organ damage: a pilot study in Japanese male self-defense force personnel.

Sci Rep. 2025. doi: 10.1038/s41598-025-91685-7.PubMed

The feasibility of point-of-care testing for initial urinary liver fatty acid-binding protein to estimate severity in severe heatstroke.

Sci Rep. 2025.doi: 10.1038/s41598-025-89767-7.PubMed

Prognostic values of proteinuria in patients with acute heart failure.

J Cardiol. 2025.doi: 10.1016/j.jjcc.2025.01.010.PubMed

The Urinary Liver-Type Fatty Acid Binding Protein (L-FABP) in Early Detection and Outcome Prediction of Sepsis-Associated Acute Kidney Injury.

Arch Acad Emerg Med. 2025.doi: https://doi.org/10.22037/aaemj.v13i1.2525SBMU Journals

Clustering based on renal and inflammatory admission parameters in critically ill patients admitted to the ICU.

PLoS One. 2024doi: 10.1371/journal.pone.0307938.PubMed

ISCCM Guidelines on Acute Kidney Injury and Renal Replacement Therapy.

Indian J Crit Care Med. 2022.doi: 10.5005/jp-journals-10071-24109.PubMed

Trajectory pattern of serially measured acute kidney injury biomarkers in critically ill patients: a prospective observational study.

Ann Intensive Care. 2024doi: 10.1186/s13613-024-01328-9. PubMed

Urinary liver-type fatty acid-binding protein level as a prognostic indicator of acute kidney injury secondary to severe falciparum malaria.

CEN Case Rep. 2024doi: 10.1007/s13730-024-00886-y. PubMed

Urinary L-FABP as an Early Biomarker for Pediatric Acute Kidney Injury Following Cardiac Surgery with Cardiopulmonary Bypass: A Systematic Review and Meta-Analysis.

Int J Mol Sci. 2024doi: 10.3390/ijms25094912. PubMed

Urinary liver-type fatty acid-binding protein levels may be associated with the occurrence of acute kidney injury induced by trauma.

Front Med (Lausanne). 2024doi: 10.3389/fmed.2024.1346183.PubMed

Urine oxygenation predicts COVID 19 risk.

Clin Exp Nephrol. 2024doi: 10.1007/s10157-023-02456-5.PubMed

Unravelling the role of urinary liver-type fatty acid binding protein in histone-induced AKI.

Nephrology (Carlton). 2024doi: 10.1111/nep.14271.PubMed

How to Construct an Optimal Risk Model for Contrast-induced Nephropathy.

Intern Med. 2024doi: 10.2169/internalmedicine.3209-23.PubMed

The Experience of Using Urinary Liver-Type Fatty Acid-Binding Protein for Follow-Up of Toluene Poisoning: A Case Report.

Cureus. 2023doi: 10.7759/cureus.50438.PubMed

Evaluation of amniotic fluid neutrophil gelatinase-associated lipocalin and L-type fatty acid-binding protein levels during pregnancy.

Eur J Obstet Gynecol Reprod Biol X. 2023doi: 10.1016/j.eurox.2023.100269.PubMed

Predictive Performance of Neutrophil Gelatinase Associated Lipocalin, Liver Type Fatty Acid Binding Protein, and Cystatin C for Acute Kidney Injury and Mortality in Severely Ill Patients.

Ann Lab Med. 2024doi: 10.3343/alm.2023.0083.PubMed

Urinary liver-type fatty acid binding protein is a biomarker reflecting renal damage and the ameliorative effect of drugs at an early stage of histone-induced acute kidney injury.

Nephrology (Carlton). 2023doi: 10.1111/nep.14254.PubMed

Subclinical and clinical acute kidney injury share similar urinary peptide signatures and prognosis.

Intensive Care Med. 2023doi: 10.1007/s00134-023-07198-2.PubMed

Biomarker array for prediction of acute kidney injury after percutaneous coronary intervention for patients who had acute ST segment elevation myocardial infarction.

Heart Vessels. 2023doi: 10.1007/s00380-023-02330-0.PubMed

Clinical usefulness of urinary biomarkers for early prediction of acute kidney injury in patients undergoing transaortic valve implantation.

Sci Rep. 2023doi: 10.1038/s41598-023-46015-0.PubMed

Elevation of Urinary Liver-Type Fatty Acid-Binding Protein Is a Harbinger of Poor Patient Prognosis after Allogeneic Stem Cell Transplantation.

Transplant Cell Ther. 2023doi: 10.1016/j.jtct.2023.10.003.PubMed

Urinary liver-type fatty acid binding protein is increased in the early stages of the disease with a risk of acute kidney injury induced by histone.

Nephrology (Carlton). 2023DOI: 10.1111/nep.14162PubMed

Urinary L-Type Fatty Acid-Binding Protein Predicts Oxygen Demand of COVID-19 in Initially Mild Cases.

Care Explor. 2023doi: 10.1097/CCE.0000000000000873.PubMed

Evaluation of Urine L-FABP Point of Care Kit in the Philippines as Predictive Marker of Clinical Severity of COVID-19 (EPOCH COVID study).

Philipp J Intern Med. 2022PJIM

Clinical utility of tubular markers in kidney disease: a narrative review.

J Lab Precis Med. 2022JLPM

Urinary liver-type fatty acid-binding protein: A hemodynamic index during extracorporeal membrane oxygenation.

Clin Case Rep. 2022doi: 10.1002/ccr3.6531PubMed

Utility of urinary liver-type fatty acid-binding protein as a prognostic marker in adult congenital heart patients hospitalized for acute heart failure.

Heart Vessels. 2022doi: 10.1007/s00380-022-02174-0PubMed

Early biomarkers for kidney injury in heat-related illness patients: a prospective observational study at Japanese Self-Defense Force Fuji Hospital.

Nephrol Dial Transplant. 2022 doi: 10.1093/ndt/gfac166.PubMed

Xanthine Oxidoreductase Activity in Marathon Runners: Potential Implications for Marathon-Induced Acute Kidney Injury.

J Appl Physiol. 2022 doi: 10.1152/japplphysiol.00669.2021.PubMed

Urinary Biomarkers Can Predict Weaning From Acute Dialysis Therapy in Critically Ill Patients.

Arch Pathol Lab Med. 2022 doi: 10.5858/arpa.2021-0411-OA.PubMed

Urine sediment findings were milder in patients with COVID-19-associated renal injuries than in those with non-COVID-19-associated renal injuries.

Int J Infect Dis. 2022 doi: 10.1016/j.ijid.2022.02.024.PubMed

Direct hemoperfusion using a polymyxin B-immobilized polystyrene column for COVID-19.

J Clin Apher. 2021 doi: 10.1002/jca.21861.PubMed

Biomarkers for the early prediction of contrast-induced nephropathy after percutaneous coronary intervention in adults: A systematic review and meta-analysis.

Angiology. 2022PubMed

Urinary L-type fatty acid-binding protein is a predictor of cisplatin-induced acute kidney injury.

BMC Nephrol. 2022 doi: 10.1186/s12882-022-02760-4.PubMed

Metformin use in patients hospitalized with COVID-19: lower inflammation, oxidative stress, and thrombotic risk markers and better clinical outcomes.

J Thromb Thrombolysis. 2022doi: 10.1007/s11239-022-02631-7.PubMed

The Role of Urine Liver Fatty Acid Binding Protein in Early Detection of Acute Kidney Injury in Septic Patient.

Egypt J Crit Care Med. 2022doi: 10.1097/EJ9.0000000000000019PubMed

Urinary liver-type fatty acid-binding protein as a prognostic marker in patients with acute heart failure.

ESC Heart Fail. 2022doi: 10.1002/ehf2.13730.PubMed

Clinical Utility of a Biomarker to Detect Contrast-Induced Acute Kidney Injury during Percutaneous Cardiovascular Procedures.

Cardiorenal Med. 2022doi: 10.1159/000520820.PubMed

Hemodynamics and Metabolic Parameters in Normothermic Kidney Preservation Are Linked With Donor Factors, Perfusate Cells, and Cytokines.

Front Med (Lausanne). 2022doi: 10.3389/fmed.2021.801098. eCollection 2021.PubMed

Quantitative and qualitative analyses of urinary L-FABP for predicting acute kidney injury after emergency laparotomy.

J Anesth. 2021doi: 10.1007/s00540-021-03003-w.PubMed

Accuracy of Liver-Type Fatty Acid-Binding Protein in Predicting Acute Kidney Injury: A Meta-Analysis.

J Appl Lab Med. 2021doi: 10.1093/jalm/jfab092.PubMed

Clinical evaluation of urinary liver-type fatty acid-binding protein for the diagnosis of renal diseases in dogs.

J Vet Med Sci. 2021PubMed

Clinical Utility of Urinary Biomarkers for Prediction of Acute Kidney Injury and Chronic Renal Dysfunction After Open Abdominal Aortic Aneurysm Repair.

Int J Nephrol Renovasc Dis. 2021doi: 10.2147/IJNRD.S322916.PubMed

Combined evaluation of plasma B-type natriuretic peptide and urinary liver-type fatty acid-binding protein/creatinine ratio isrelated to worsening renal function in patients undergoing elective percutaneous coronary intervention.

Clin Exp Nephrol. 2021doi: 10.1007/s10157-021-02113-9.PubMed

First Experience Addressing the Prognostic Utility of Novel Urinary Biomarkers in Patients With COVID-19.

Open Forum Infect Dis. 2021doi: 10.1093/ofid/ofab274.PubMed

COVID-19-induced acute renal tubular injury associated with elevation of serum inflammatory cytokine.

Clin Exp Nephrol. 2021doi: 10.1007/s10157-021-02101-z.PubMed

Assessment of Cardiopulmonary Bypass Duration Improves Novel Biomarker Detection for Predicting Postoperative Acute Kidney Injury after Cardiovascular Surgery.

J Clin Med. 2021doi: 10.3390/jcm10132741.PubMed

Urinary liver-type fatty acid-binding protein variation as a predictive value of short-term mortality in intensive care unit patients.

Ren Fail. 2021doi: 10.1080/0886022X.2021.1943439.PubMed

Urinary liver-type fatty acid-binding protein is independently associated with graft failure in outpatient kidney transplant recipients.

Am J Transplant. 2020doi: 10.1111/ajt.16312.PubMed

Urinary biomarkers of kidney tubule injury, risk of acute kidney injury, and mortality in patients with acute ischaemic stroke treated at a stroke care unit.

Eur J Neurol. 2020doi: 10.1111/ene.14448.PubMed

Evaluation of Coronavirus Disease 2019 Severity Using Urine Biomarkers.

Crit Care Explor. 2020doi: 10.1097/CCE.0000000000000170.PubMed

Urinary Liver-Type Fatty-Acid-Binding Protein Predicts Long-Term Adverse Outcomes in Medical Cardiac Intensive Care Units.

J Clin Med. 2020PubMed

Novel Urinary Biomarkers for Acute Kidney Injury and Prediction of Clinical Outcomes After Pediatric Cardiac Surgery.

Pediatr Cardiol. 2019PubMed

Disrupted tubular parathyroid hormone/parathyroid hormone receptor signaling and damaged tubular cell viability possibly trigger postsurgical kidney injury in patients with advanced hyperparathyroidism.

Clin Kidney J. 2019PubMed

Temporal changes in urinary excretion of liver-type fatty acid binding protein (L-FABP) in acute kidney injury model of domestic cats: a preliminary study.

J Vet Med Sci. 2019PubMed

Clinical significance of urinary L-FABP in the emergency department.

Int J Emerg Med. 2019PubMed

Effect of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on cisplatin-induced nephrotoxicity in mice.

Naunyn Schmiedebergs Arch Pharmacol. 2018PubMed

Predicting acute kidney injury using urinary liver-type fatty-acid binding protein and serum N-terminal pro-B-type natriuretic peptide levels in patients treated at medical cardiac intensive care units.

Crit Care. 2018PubMed

Increased urinary liver-type fatty acid-binding protein level predicts worsening renal function in patients with acute heart failure.

J Card Fail. 2018PubMed

Urinary Liver Type Fatty Acid Binding Protein Is Negatively Associated With Estimated Glomerular Filtration Rate in Renal Transplant Recipients With Graft Loss.

Transplant Proc. 2018PubMed

Biomarkers of AKI Progression after Pediatric Cardiac Surgery.

J Am Soc Nephrol. 2018PubMed

Urinary Liver-Type Fatty Acid-Binding Protein Level as a Predictive Biomarker of Acute Kidney Injury in Patients with Acute Decompensated Heart Failure.

Cardiorenal Med. 2017PubMed

Prediction of contrast induced acute kidney injury using novel biomarkers following contrast coronary angiography.

QJM. 2018PubMed

Urinalysis findings and urinary kidney injury biomarker concentrations.

BMC Nephrol. 2017PubMed

Values of combination of urinary L-FABP and NGAL in early diagnosis of acute kidney injury after cardiac surgery in children.

Scand J Clin Lab Invest. 2017PubMed

Utility of urinary tubular markers for monitoring chronic tubulointerstitial injury after ischemia-reperfusion.

Nephrology. 2017PubMed

The protective effect of human atrial natriuretic peptide on renal damage during cardiac surgery.

J Anesth. 2016PubMed

Storage Time and Urine Biomarker Levels in the ASSESS-AKI Study.

PLoS One. 11(10), 2016PubMed

Urinary l-type fatty acid-binding protein is a predictor of early renal function after partial nephrectomy.

Ren Fail. 1-6, 2016PubMed

Impact of clinical context on acute kidney injury biomarker performances: differences between neutrophil gelatinase-associated lipocalin and L-type fatty acid-binding protein.

Sci Rep. 2016PubMed

First Post-Operative Urinary Kidney Injury Biomarkers and Association with the Duration of AKI in the TRIBE-AKI Cohort.

PLoS One. 11(8):e0161098PubMed

Acute Kidney Injury after Cardiac Surgery: Risk Factors and Novel Biomarkers.

Braz J Cardiovasc Surg. 2019PubMed

The ischemic/nephrotoxic Acute Kidney Injury and the use of renal biomarkers in clinical practice.

Eur J Intern Med. 2016PubMed

The potential use of biomarkers in predicting contrast-induced acute kidney injury.

Int J Nephrol Renovasc Dis. 2016PubMed

Biomarkers in acute kidney injury ? pathophysiological basis and clinical performance.

Acta Physiol. 2016PubMed

Bench to Bedside: The next steps for biomarkers in acute kidney injury.

Am J Physiol Renal Physiol. 311(4):F717-F721, 2016PubMed

Comparison of three early biomarkers for acute kidney injury after cardiac surgery under cardiopulmonary bypass.

J Intensive Care. 4(41), 2016.PubMed

Novel urinary tubular injury markers reveal an evidence of underlying kidney injury in children with reduced left ventricular systolic function: a pilot study.

Pediatr Nephrol. 2016.PubMed

Urinary L-FABP as a mortality predictor among < 5 septic children in Bangladesh.

Pediatr Int. 185-191, 2016.PubMed

Follow-Up Renal Assessment of Injury Long-Term After Acute Kidney Injury (FRAIL-AKI).

Clin J Am Soc Nephrol. 11(1):21-29, 2015.PubMed

Clinical usefulness of urinary liver-type fatty-acid-binding protein as a perioperative marker of acute kidney injury in patients undergoing endovascular or open-abdominal aortic aneurysm repair.

J Anesth. 30(1): 89-99. 2015.PubMed

Urinary, Plasma, and Serum Biomarkers’ Utility for Predicting Acute Kidney Injury Associated With Cardiac Surgery in Adults: A Meta-analysis.

Am J Kidney Dis. 66(6):993-1005, 2015.PubMed

Elevation of urinary liver-type fatty acid binding protein after cardiac catheterization related to cardiovascular events.

Int J Nephrol Renovasc Dis. 8: 91-99, 2015.PubMed

Response of urinary liver-type fatty acid-binding protein to contrast media administration has a potential to predict one-year renal outcome in patients with ischemic heart disease.

Heart Vessels. 30(3): 296-303, 2015.PubMed

Assessment of Worldwide Acute Kidney Injury, Renal Angina and Epidemiology in Critically Ill Children (AWARE): study protocol for a prospective observational study.

BMC Nephrol. 16(24), 2015.PubMed

Pediatric reference ranges for acute kidney injury biomarkers.

Pediatr Nephrol. 30(4): 677-685, 2015.PubMed

Human liver-type fatty acid-binding protein protects against tubulointerstitial injury in aldosterone-induced renal injury.

Am J Physiol Renal Physiol. 308(2): F114-121, 2014.PubMed

Early prediction of acute kidney injury biomarkers after endovascular stent graft repair of aortic aneurysm: a prospective observational study.

J Intensive Care. 2(45), 2014.PubMed

Urinary liver-type fatty acid-binding protein linked with increased risk of acute kidney injury after allogeneic stem cell transplantation.

Biol Blood Marrow Transplant. 20(12): 2010-2014, 2014.PubMed

A newly developed kit for the measurement of urinary liver-type fatty acid-binding protein as a biomarker for acute kidney injury in patients with critical care.

J Infect Chemother. 21(3): 165-169, 2014.PubMed

Urinary L-FABP predicts poor outcomes in critically ill patients with early acute kidney injury.

Kidney Int. 87(3): 640-648, 2014.PubMed

Repulsive guidance cue semaphorin 3A in urine predicts the progression of acute kidney injury in adult patients from a mixed intensive care unit.

Nephrol Dial Transplant. 29(1): 73-80, 2014.PubMed

Urinary biomarkers and progression of AKI in patients with cirrhosis.

Clin J Am Soc Nephrol. 9(11): 1857-1867, 2014.PubMed

Biomarkers of acute kidney injury in pediatric cardiac surgery.

Clin Biochem. 46(13-14): 1244-1251, 2013.PubMed

Performance of urinary liver-type fatty acid-binding protein in acute kidney injury: a meta-analysis.

Am J Kidney Dis. 61(3): 430-439, 2013.PubMed

Performance of kidney injury molecule-1 and liver fatty acid-binding protein and combined biomarkers of AKI after cardiac surgery.

Clin J Am Soc Nephrol. 8(7): 1079-1088, 2013.PubMed

Remote Ischemic Pre-Conditioning Alleviates ContrastInduced Acute Kidney Injury in Patients With Moderate Chronic Kidney Disease.

Circulation Journal. 77(12): 3037-3044, 2013.PubMed

The role of urinary liver-type fatty acid-binding protein in critically ill patients.

J Korean Med Sci. 28(1): 100-105, 2013.PubMed

Clinical significance of the measurements of urinary liver-type fatty acid binding protein levels in patients with acute coronary syndrome.

J Cardiol. 60(3): 168-173, 2012.PubMed

Urinary liver-type fatty acid-binding protein level as a predictive biomarker of contrast-induced acute kidney injury.

Eur J Clin Invest. 42(5): 557-563, 2012.PubMed

Usefulness of Urinary Biomarkers in Early Detection of Acute Kidney Injury After Cardiac Surgery in Adults.

Circulation Journal. 76(1): 213-220, 2012.PubMed

Combination of two urinary biomarkers predicts acute kidney injury after adult cardiac surgery.

Ann Thorac Surg. 93(2): 577-583, 2012.PubMed

Renal liver-type fatty acid binding protein attenuates angiotensin II-induced renal injury.

Hypertension. 60(4): 973-980, 2012.PubMed

Mild elevation of urinary biomarkers in prerenal acute kidney injury.

Kidney Int. 82(10): 1114-1120, 2012.PubMed

Temporal relationship and predictive value of urinary acute kidney injury biomarkers after pediatric cardiopulmonary bypass.

J Am Coll Cardiol. 58(22): 2301-2309, 2011.PubMed

Renal liver-type fatty acid binding protein (L-FABP) attenuates acute kidney injury in aristolochic acid nephrotoxicity.

Am J Pathol. 178(3): 1021-1032, 2011.PubMed

Clinical significance of tubular and podocyte biomarkers in acute kidney injury.

Clin Exp Nephrol. 15(2): 220-225, 2011.PubMed

Evaluation of new acute kidney injury biomarkers in a mixed intensive care unit.

Crit Care Med. 39(11): 2464-2469, 2011.PubMed

Urinary L-type fatty acid-binding protein as a new biomarker of sepsis complicated with acute kidney injury.

Crit Care Med. 38(10): 2037-2042, 2010PubMed

Urinary excretion of liver type fatty acid binding protein accurately reflects the degree of tubulointerstitial damage.

Am J Pathol. 174(6): 2096-2106, 2009.PubMed

Urinary L-type fatty acid-binding protein can reflect renal tubulointerstitial injury.

Am J Pathol. 174(4): 1203-1211, 2009.PubMed

Monitoring of urinary L-type fatty acid-binding protein predicts histological severity of acute kidney injury.

Am J Pathol. 174(4): 1154-1159, 2009.PubMed

Urinary liver-type fatty acid-binding protein in septic shock: effect of polymyxin B-immobilized fiber hemoperfusion.

Shock. 31(5): 454-459, 2009.PubMed

Urinary human L-FABP is a potential biomarker to predict COX-inhibitor-induced renal injury.

Nephron Exp Nephrol. 108(1): e19-26, 2008.PubMed

Liver fatty acid-binding protein as a biomarker of acute kidney injury after cardiac surgery.

Kidney Int. 73(4): 465-472, 2008.PubMed

Renal L-type fatty acid-binding protein mediates the bezafibrate reduction of cisplatin-induced acute kidney injury.

Kidney Int. 73(12): 1374-1384, 2008.PubMed

L-Type Fatty Acid Binding Protein Transgenic Mouse as a Novel Tool to Explore Cytotoxicity to Renal Proximal Tubules.

Drug Metab. Pharmacokinet. 23(4): 271-278, 2008.PubMed

Renal L-type fatty acid-binding protein in acute ischemic injury.

J Am Soc Nephrol. 18(11): 2894-2902, 2007.PubMed

A role of liver fatty acid-binding protein in cisplatin-induced acute renal failure.

Kidney Int. 72(3): 348-358, 2007.PubMed

Urinary excretion of liver-type fatty acid-binding protein in contrast medium-induced nephropathy.

Am J Kidney Dis. 47(3): 439-444, 2006.PubMed

Quantification of L-type fatty acid binding protein in the urine of preterm neonates.

Early Hum Dev. 81(7): 643-646, 2005.PubMed

Urinary biomarkers in prediction of subclinical acute kidney injury in pediatric oncology patients treated with nephrotoxic agents.

BMC Nephrol. 2025. doi: 10.1186/s12882-025-04085-4.PubMed

Urinary liver-type fatty acid-binding protein in two dogs with acquired Fanconi syndrome: A case report.

Open Vet J. 2022doi: 10.5455/OVJ.2022.v12.i6.12 PubMed

Urinary L-type fatty acid-binding protein is a predictor of cisplatin-induced acute kidney injury.

BMC Nephrol. 2022 doi: 10.1186/s12882-022-02760-4.PubMed

Clinical Utility of a Biomarker to Detect Contrast-Induced Acute Kidney Injury during Percutaneous Cardiovascular Procedures.

Cardiorenal Med. 2022doi: 10.1159/000520820.PubMed

Changing trends in lipid profile and biomarkers of renal function and bone metabolism before and after switching from tenofovir disoproxil fumarate to tenofovir alafenamide: a prospective observational study.

AIDS Res Ther. 2021 doi: 10.1186/s12981-021-00354-y.PubMed

Early changes in tubular dysfunction markers and phosphorus metabolism regulators as a result of switching from entecavir to tenofovir alafenamide fumarate nucleoside analog therapy for chronic hepatitis B patients.

Hepatol Res. 2020 doi: 10.1111/hepr.13451.PubMed

The influence of renal function by ibuprofen treatment for patent ductus arteriosus in extremely low-birth-weight infants.

Pediatr Int. 2019PubMed

Utility of urinary liver-type fatty acid-binding protein as a predictor of renal dysfunction in Japanese patients with HIV receiving tenofovir disoproxil fumarate with low urinary β2 microglobulin levels: a retrospective observational study.

J Pharm Health Care Sci. 2019PubMed

Biomarkers of drug-induced kidney toxicity.

Ther Drug Monit. 2018PubMed

The ischemic/nephrotoxic Acute Kidney Injury and the use of renal biomarkers in clinical practice.

Eur J Intern Med. 2016PubMed

The potential use of biomarkers in predicting contrast-induced acute kidney injury.

Int J Nephrol Renovasc Dis. 2016PubMed

Renoprotective effect of the xanthine oxidoreductase inhibitor, Topiroxostat,on Adenine-Induced Renal Injury.

Am J Physiol Renal Physiol. 310(11):F1366-1376, 2016.PubMed

Response of urinary liver-type fatty acid-binding protein to contrast media administration has a potential to predict one-year renal outcome in patients with ischemic heart disease.

Heart Vessels. 30(3): 296-303, 2015.PubMed

Human liver-type fatty acid-binding protein protects against tubulointerstitial injury in aldosterone-induced renal injury.

Am J Physiol Renal Physiol. 308(2): F114-121, 2014.PubMed

Urine liver-type fatty acid-binding protein and kidney injury molecule-1 in HIV-infected patients receiving combined antiretroviral treatment based on tenofovir.

AIDS Res Hum Retroviruses. 30(4): 363-369, 2014.PubMed

Remote Ischemic Pre-Conditioning Alleviates ContrastInduced Acute Kidney Injury in Patients With Moderate Chronic Kidney Disease.

Circulation Journal. 77(12): 3037-3044, 2013.PubMed

Urinary liver-type fatty acid-binding protein level as a predictive biomarker of contrast-induced acute kidney injury.

Eur J Clin Invest. 42(5): 557-563, 2012.PubMed

Renal liver-type fatty acid binding protein (L-FABP) attenuates acute kidney injury in aristolochic acid nephrotoxicity.

Am J Pathol. 178(3): 1021-1032, 2011.PubMed

Urinary excretion of liver type fatty acid binding protein accurately reflects the degree of tubulointerstitial damage.

Am J Pathol. 174(6): 2096-2106, 2009.PubMed

Monitoring of urinary L-type fatty acid-binding protein predicts histological severity of acute kidney injury.

Am J Pathol. 174(4): 1154-1159, 2009.PubMed

Urinary human L-FABP is a potential biomarker to predict COX-inhibitor-induced renal injury.

Nephron Exp Nephrol. 108(1): e19-26, 2008.PubMed

Renal L-type fatty acid-binding protein mediates the bezafibrate reduction of cisplatin-induced acute kidney injury.

Kidney Int. 73(12): 1374-1384, 2008.PubMed

L-Type Fatty Acid Binding Protein Transgenic Mouse as a Novel Tool to Explore Cytotoxicity to Renal Proximal Tubules.

Drug Metab. Pharmacokinet. 23(4): 271-278, 2008.PubMed

A role of liver fatty acid-binding protein in cisplatin-induced acute renal failure.

Kidney Int. 72(3): 348-358, 2007.PubMed

Urinary excretion of liver-type fatty acid-binding protein in contrast medium-induced nephropathy.

Am J Kidney Dis. 47(3): 439-444, 2006.PubMed

Topiroxostat-A Safer Uricostatic Drug with Enhanced Renal Protection: A Narrative Review.

J Assoc Physicians India. 2024doi: 10.59556/japi.72.0724.PubMed

Urinary liver-type fatty acid binding protein is a biomarker reflecting renal damage and the ameliorative effect of drugs at an early stage of histone-induced acute kidney injury.

Nephrology (Carlton). 2023doi: 10.1111/nep.14254.PubMed

Markers of Kidney Tubular Function Deteriorate While Those of Kidney Tubule Health Improve in Primary Aldosteronism After Targeted Treatments.

J Am Heart Assoc. 2023PubMed

Association of urinary liver-type fatty acid-binding protein with renal functions and antihyperglycemic drug use in type 2 diabetic nephropathy patients.

Int Urol Nephrol. 2023PubMed

Tubular Injury Causing Protracted Glycosuria Following Withdrawal of a Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor: A Possible Role in the Development of Protracted Hypoglycemia and Ketoacidosis.

Tohoku J Exp Med. 2021PubMed

Effect of Dipeptidyl Peptidase-4 (DPP-4) Inhibition on Biomarkers of Kidney Injury and Vascular Calcification in Diabetic Kidney Disease: A Randomized Controlled Trial.

J Diabetes Res. 2021doi: 10.1155/2021/7382620. PubMed

Effect of linagliptin on oxidative stress markers in patients with type 2 diabetes: a pilot study.

Diabetol Int. 2018PubMed

Effect of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on cisplatin-induced nephrotoxicity in mice.

Naunyn Schmiedebergs Arch Pharmacol. 2018PubMed

Anagliptin ameliorates albuminuria and urinary liver-type fatty acid-binding protein excretion in patients with type 2 diabetes with nephropathy in a glucoselowering-independent manner.

BMJ Open Diabetes Res Care. 2017PubMed

Role of bardoxolone methyl, a nuclear factor erythroid 2-related factor 2 activator, in aldosterone- and salt-induced renal injury.

Hypertens Res. 2017PubMed

Renoprotective effect of the xanthine oxidoreductase inhibitor Topiroxostat under decreased angiotensin II type 1a receptor expression.

Eur J Pharmacol. 2017PubMed

The protective effect of human atrial natriuretic peptide on renal damage during cardiac surgery.

J Anesth. 2016PubMed

The association between urinary liver-type fatty acid-binding protein and chronic kidney disease classification in HIV-infected Japanese patients.

Clin Exp Nephrol. 2016PubMed

Impact of teneligliptin on oxidative stress and endothelial function in type 2 diabetes patients with chronic kidney disease: a case-control study.

Cardiovasc Diabetol. 15(1): 76, 2016.PubMed

Renoprotective effect of the xanthine oxidoreductase inhibitor, Topiroxostat,on Adenine-Induced Renal Injury.

Am J Physiol Renal Physiol. 310(11):F1366-1376, 2016.PubMed

Epoetin beta pegol alleviates oxidative stress and exacerbation of renal damage from iron deposition, thereby delaying CKD progression in progressive glomerulonephritis rats.

Physiol Rep. 3(12), 2015.PubMed

Urinary ACE2 is associated with urinary L-FABP and albuminuria in patients with chronic kidney disease.

Scand J Clin Lab Invest. 75(5): 421-427, 2015.PubMed

Does elevation of serum creatinine in patients with chronic hepatitis C under therapy of telaprevir mean renal impairment?

Nephrology. 10(4):e0122212, 2015.PubMed

Renoprotective effects of febuxostat in hyperuricemic patients with chronic kidney disease: a parallel-group, randomized, controlled trial.

Clin Exp Nephrol. 19(6): 1044-1053, 2015.PubMed

A 5-hydroxytryptamine receptor antagonist, sarpogrelate, reduces renal tubulointerstitial fibrosis by suppressing PAI-1.

Am J Physiol Renal Physiol. 305(12): F1796-1803, 2013.PubMed

Spironolactone diminishes urinary albumin excretion in patients with type 1 diabetes and microalbuminuria: a randomized placebo-controlled crossover study.

Diabet Med. 29(8): e184-190, 2012.PubMed

Renoprotective and antioxidant effects of cilnidipine in hypertensive patients.

Hypertens Res. 35(11): 1058-1062, 2012.PubMed

Potential Benefit of Statin Therapy for Dyslipidemia with Chronic Kidney Disease: Fluvastatin Renal Evaluation Trial (FRET).

Internal Medicine. 50(12): 1273-1278, 2011.PubMed

Additive antioxidative effects of azelnidipine on angiotensin receptor blocker olmesartan treatment for type 2 diabetic patients with albuminuria.

Hypertens Res . 34: 935-941, 2011.PubMed

Comparative effects of benidipine and amlodipine on proteinuria, urinary 8-OHdG, urinary L-FABP, and inflammatory and atherosclerosis markers in early-stage chronic kidney disease.

Am J Med Sci. 339(2): 157-163, 2010.PubMed

Renoprotective Effects of Various Angiotensin II Receptor Blockers in Patients with Early-Stage Diabetic Nephropathy.

Kidney Blood Press Res. 33(3): 213-220, 2010.PubMed

Effects of telmisartan and enalapril on renoprotection in patients with mild to moderate chronic kidney disease.

Eur J Clin Invest. 40(9): 790-796, 2010.PubMed

Urinary L-type fatty acid-binding protein can reflect renal tubulointerstitial injury.

Am J Pathol. 174(4): 1203-1211, 2009.PubMed

Tubular and glomerular injury in diabetes and the impact of ACE inhibition.

Diabetes Care. 32(9): 1684-1688, 2009.PubMed

Renal L-type fatty acid-binding protein mediates the bezafibrate reduction of cisplatin-induced acute kidney injury.

Kidney Int. 73(12): 1374-1384, 2008.PubMed

Renoprotective effect of telmisartan in patients with chronic kidney disease.

Clin Exp Hypertens. 30(7): 662-672, 2008.PubMed

Additional renoprotective effects of azelnidipine combined with angiotensin receptor blockers in patients with diabetic nephropathy.

Clin Nephrol. 70(5): 385-392, 2008.PubMed

Angiotensin II receptor antagonist reduces urinary liver-type fatty acid-binding protein levels in patients with diabetic nephropathy and chronic renal failure.

Diabetologia. 50(2): 490-492, 2007.PubMed

Azelnidipine reduces urinary protein excretion and urinary liver-type fatty acid binding protein in patients with hypertensive chronic kidney disease.

Am J Med Sci. 333(6): 321-326, 2007.PubMed

Beneficial effects of olmesartan and temocapril on urinary liver-type fatty acid-binding protein levels in normotensive patients with immunoglobin A nephropathy.

Am J Hypertens. 20(11): 1195-1201, 2007.PubMed

Urinary liver-type fatty acid-binding protein levels for differential diagnosis of idiopathic focal glomerulosclerosis and minor glomerular abnormalities and effect of low-density lipoprotein apheresis.

Clin Nephrol. 65(1): 1-6, 2006.PubMed

Effect of pioglitazone on urinary liver-type fatty acid-binding protein concentrations in diabetes patients with microalbuminuria.

Diabetes Metab Res Rev. 22(5): 385-389, 2006.PubMed

Effect of Erythropoietin on Urinary Liver-Type Fatty-Acid-Binding Protein in Patients with Chronic Renal Failure and Anemia.

Am J Nephrol. 26(3): 276-280, 2006.PubMed

Effect of pitavastatin on urinary liver-type fatty-acid-binding protein in patients with nondiabetic mild chronic kidney disease.

Am J Nephrol. 26(1): 82-86, 2006.PubMed

Candesartan reduces urinary fatty acid-binding protein excretion in patients with autosomal dominant polycystic kidney disease.

TAm J Med Sci. 330(4): 161-165, 2005.PubMed

Effect of Pitavastatin on Urinary Liver-Type Fatty acid-binding Protein Levels in Patients With Early Diabetic Nephropathy.

Diabetes Care. 28(11): 2728-2732, 2005.PubMed

Liver fatty acid-binding protein point-of-care testing detects heat-induced organ damage: a pilot study in Japanese male self-defense force personnel.

Sci Rep. 2025. doi: 10.1038/s41598-025-91685-7.PubMed

The feasibility of point-of-care testing for initial urinary liver fatty acid-binding protein to estimate severity in severe heatstroke.

Sci Rep. 2025.doi: 10.1038/s41598-025-89767-7.PubMed

The moderate-intensity continuous exercise maintains renal blood flow and does not impair the renal function .

Physiol Rep. 2022doi: 10.14814/phy2.15420.PubMed

Early biomarkers for kidney injury in heat-related illness patients: a prospective observational study at Japanese Self-Defense Force Fuji Hospital.

Nephrol Dial Transplant. 2022 doi: 10.1093/ndt/gfac166.PubMed

Xanthine Oxidoreductase Activity in Marathon Runners: Potential Implications for Marathon-Induced Acute Kidney Injury.

J Appl Physiol. 2022 doi: 10.1152/japplphysiol.00669.2021.PubMed

Wearing a face mask during controlled-intensity exercise is not a risk factor for exertional heatstroke: A pilot study.

Acute Med Surg. 2021doi: 10.1002/ams2.712.PubMed

Exercise Ameliorates Diabetic Kidney Disease in Type 2 Diabetic Fatty Rats.

Antioxidants (Basel). 2021PubMed

Effects of exercise on residual renal function in patients undergoing peritoneal dialysis: a post-hoc analysis of a randomized controlled trial.

Ther Apher Dial. 2020PubMed

慢性腎臓病の重症化予防に向けた運動の役割

体力科学誌 2019

習慣的な運動による老化関連疾患の予防

医学のあゆみ 2018

Renoprotective effects of voluntary running exercise training on aldosterone-induced renal injury in human L-FABP chromosomal transgenic mice.

Hypertens Res. 2019PubMed

Urinary liver-type fatty acid-binding protein is associated with subendocardial viability ratio in middle- and older-aged adults.

Clin Exp Hypertens. 2017PubMed

Effect of habitual exercise on urinary liver-type fatty acid-binding protein levels in middle-aged and older adults.

Scand J Med Sci Sports. 2017PubMed

Relationship between exercise capacity and urinary liver-type fatty acid-binding protein in middle-aged and older individuals.

Clin Exp Nephrol. 2017PubMed

Moderate-intensity single exercise session does not induce renal damage.

J Clin Lab Anal. 27(3): 177-180, 2013.PubMed

Clustering based on renal and inflammatory admission parameters in critically ill patients admitted to the ICU.

PLoS One. 2024doi: 10.1371/journal.pone.0307938.PubMed

Urine oxygenation predicts COVID 19 risk.

Clin Exp Nephrol. 2024doi: 10.1007/s10157-023-02456-5.PubMed

Urinary liver-type fatty acid binding protein is a biomarker reflecting renal damage and the ameliorative effect of drugs at an early stage of histone-induced acute kidney injury.

Nephrology (Carlton). 2023doi: 10.1111/nep.14254.PubMed

当院でのcovid-19入院患者から検討した重症化予測因子

内科 2023

Urinary liver-type fatty acid binding protein is increased in the early stages of the disease with a risk of acute kidney injury induced by histone.

Nephrology (Carlton). 2023DOI: 10.1111/nep.14162PubMed

Urinary L-Type Fatty Acid-Binding Protein Predicts Oxygen Demand of COVID-19 in Initially Mild Cases.

Care Explor. 2023doi: 10.1097/CCE.0000000000000873.PubMed

Evaluation of Urine L-FABP Point of Care Kit in the Philippines as Predictive Marker of Clinical Severity of COVID-19 (EPOCH COVID study).

Philipp J Intern Med. 2022PJIM

COVID－19と高血圧症・腎疾患

The Lipid 33(1) 2022

Urine sediment findings were milder in patients with COVID-19-associated renal injuries than in those with non-COVID-19-associated renal injuries.

Int J Infect Dis. 2022 doi: 10.1016/j.ijid.2022.02.024.PubMed

Direct hemoperfusion using a polymyxin B-immobilized polystyrene column for COVID-19.

J Clin Apher. 2021 doi: 10.1002/jca.21861.PubMed

Metformin use in patients hospitalized with COVID-19: lower inflammation, oxidative stress, and thrombotic risk markers and better clinical outcomes.

J Thromb Thrombolysis. 2022doi: 10.1007/s11239-022-02631-7.PubMed

First Experience Addressing the Prognostic Utility of Novel Urinary Biomarkers in Patients With COVID-19.

Open Forum Infect Dis. 2021doi: 10.1093/ofid/ofab274.PubMed

COVID-19-induced acute renal tubular injury associated with elevation of serum inflammatory cytokine.

Clin Exp Nephrol. 2021doi: 10.1007/s10157-021-02101-z.PubMed

Evaluation of Coronavirus Disease 2019 Severity Using Urine Biomarkers.

Crit Care Explor. 2020doi: 10.1097/CCE.0000000000000170.PubMed

尿細管マーカーの見方

臨床検査 68(4) 2024

犬における尿中L-FABPの臨床的意義

未病の科学 3 2024

未病と尿中L-FABP

未病の科学 3 2024

バイオマーカーが捉える心血管疾患患者における急性腎障害

臨床化学 52(1) 2023

腎臓病の克服を目指して

金沢大学十全医学会雑誌 132(1) 2023

当院でのcovid-19入院患者から検討した重症化予測因子

内科 2023

COVID－19と高血圧症・腎疾患

The Lipid 33(1) 2022

【CKD 患者における抗がん薬治療】がん薬物療法前のAKIリスク評価とAKIバイオマーカー

腎と透析93(3) 2022

慢性腎臓病の重症化予防に向けた運動の役割

体力科学誌 2019

習慣的な運動による老化関連疾患の予防

医学のあゆみ 2018

SGLT2 阻害薬ルセオグリフロジンの腎機能障害合併2 型糖尿病患者に対する有用性の検討

診療と新薬55, 2018

ヒト腎障害バイオマーカーL-FABP（Liver-Type Fatty Acid-Binding Protein）の非臨床安全性試験への応用

谷本学校 毒性質問箱第19号, 2017

ヒトL型脂肪酸結合蛋白 (L-FABP) キット「ルミパルスL-FABP」の基礎的検討

日本臨床検査自動化学会会誌42(1), 2017

糖尿病腎症・CKDバイオマーカーの有用性 尿中L型脂肪酸結合蛋白(尿中L-FABP)

プラクティス33(3), 2016

糖尿病性腎症の早期診断における尿検査

臨牀と研究93(8), 2016

尿中肝型脂肪酸結合蛋白 (L-FABP) 測定試薬「ノルディア(R)L-FABP」の基礎的検討

臨床検査63(3), 2016

高血圧患者におけるテルミサルタンが炎症 腎機能マーカーに与える影響

血圧.23(1): 56-60, 2016

高血圧患者の尿中マーカーに対するアンジオテンシンII受容体拮抗薬(ARB)イルベサルタンの効果.

日本腎臓学会誌.58(2): 104-113, 2016.

急性間質性肺炎に対するpolymyxin B immobilized fiber column direct hemoperfusion (PMX-DHP)療法の治療経過を尿中L-type fatty acid binding protein (L-FABP)の推移から観察し得た1例.

日本急性血液浄化学会雑誌.6(1): 86-89, 2015.

L-FABPによるレドックス制御

別冊「医学のあゆみ」レドックスUPDATE ストレス制御の臨床医学・健康科学198-201, 2015.

CKDバイオマーカー：尿中L-FABP―分子機構から臨床的意義まで―

日本薬理学雑誌146: 27-32, 2015.

腎疾患のバイオマーカー：尿中L-FABP

腎臓内科・泌尿器科1(3): 247-252, 2015.

高血圧合併糖尿病腎症患者におけるイルベサルタンの多面的作用

血圧21(6): 543-548, 2014.

新規に保険収載された尿中L-FABPの臨床的有用性

日本臨床検査自動化学会誌39(2): 178-182, 2014.

糖尿病性腎症のバイオマーカー

臨床病理62(2): 171-179, 2014.

L-FABPと腎臓病

臨床病理62(2): 163-170, 2014.

薬剤性腎障害のメカニズムと尿中のバイオマーカー.

薬事.55(13), 2013.

脂肪酸結合タンパクファミリー

肥満研究19(3): 167-174, 2013.

臨床検査の大物新星、久々に登場―尿中L-FABP（腎機能低下リスクの判別に有用）―

検診たより13(22-24), 2013.

尿中バイオマーカー 尿中L-FABPの臨床的有用性

Medical Technology41(8): 825-826, 2013.

尿中L-fatty acid binding proteinによる病態解析

臨床検査57(6): 623-629, 2013.

保険収載された新規バイオマーカー尿中L-FABPの臨床的有用性

臨床病理61(7): 635-640, 2013.

腎虚血バイオマーカーとしてのL-FABP

Medical Science Digest39(10): 38-41, 2013.

脂質異常症を合併したIgA腎症患者におけるHMG-CoA還元酵素阻害薬とロサルタンとの併用における腎保護効果を検討する多施設共同研究(LIPS研究)―中間報告2―.

Therapeutic Research.33(8): 1218-1219, 2012.

脂質異常症を合併したIgA腎症患者におけるHMG-CoA還元酵素阻害薬とロサルタンとの併用における腎保護効果を検討する多施設共同研究－LIPS研究 (Losartan lgA nephropathy Protection with Statin Study)中間報告―.

Therapeutic Research.33(2): 209-210, 2012.

Disease biomarkers for CKD.

日本臨床検査自動化学会会誌.70(5): 864-868, 2012.

血液浄化療法紹介：第1回 CRRT（持続的腎代替療法）

旭化成メディカル株式会社 医療従事者向け情報誌 Rapport7(15-16), 2012.

新規に保険収載された尿中バイオマーカー：尿中L型脂肪酸結合蛋白

モダンメディア58(4): 123-126, 2012.

尿バイオマーカーのパネル化

Annual Review 腎臓86-93, 2011.

CKDにおけるバイオマーカー

腎と透析70(2): 171-174, 2011.

腎疾患のバイオマーカー開発の最前線

細胞42(4): 154-156, 2010.

尿中バイオマーカーのパネル化による疾患管理戦略

PHARM STAGE10(5): 55-58, 2010.

バイオマーカーと治療指針

Mebio27(1): 58-63, 2010.

AKI早期診断のための尿バイオマーカーパネル

医学のあゆみ231(2): 154-157, 2009.

注目される新しい検査 4. 尿細管マーカー 1) 尿中L型脂肪酸結合蛋白（L-FABP）

Medical Technology37(6): 584-587, 2009.

CKDの新しいバイオマーカー

Modern Physician28(8): 1159-1162, 2008.

尿中L型脂肪酸結合蛋白（L-FABP）の臨床的意義―新しい尿細管指標

Medical Technology36(4): 346-347, 2008.

尿中肝型脂肪酸結合蛋白排泄に及ぼす血管造影剤の影響

日本腎臓学会誌47(4): 437-444, 2005.

尿中脂肪による尿細管間質障害

Annual Review 腎臓81-84, 2005.

尿中肝臓型脂肪酸結合蛋白（L-FABP）

日本臨床62(11): 123-125, 2004.

尿中肝臓型脂肪酸結合蛋白（L-FABP）の臨床的意義

Lab. Clin. Pract.21(1): 12-15, 2003.

尿中肝臓型脂肪酸結合蛋白（L-FABP）の臨床的意義

臨床病理51(3): 219-224, 2003.

脂肪酸結合蛋白質（FABP）

日本臨床59(2): 245-250, 2001.

脂肪酸結合蛋白に着目した腎疾患治療薬開発の試み

細胞33(1): 24-27, 2001.